A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2017
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms COMPLEMENT 2
- Sponsors GlaxoSmithKline; Novartis
- 25 Jun 2017 Results of assessment of clinical associations of gene mutations in this trial presented at the 22nd Congress of the European Haematology Association.
- 07 Jun 2017 This trial has been completed in Spain.
- 31 Jan 2017 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History